ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Basic/Clinical Science Session

Fibroblast Growth Factor 23 and Outcomes: New Answers, New Questions, Including the Jack W. Coburn, MD, Endowed Lectureship

November 07, 2019 | 02:00 PM - 04:00 PM

Location: 145, Walter E. Washington Convention Center

Session Description

Fibroblast growth factor 23 (FGF-23) is a bone-derived hormone suppressing phosphate reabsorption and vitamin D hormone synthesis in the kidney. It is well established that excessive concentrations of intact FGF-23 in the blood lead to phosphate wasting in patients with normal kidney function. Regulators of FGF-23 production include parathyroid hormone (PTH), vitamin D, dietary phosphate, and inflammation. This session discusses new regulatory actions and implications of FGF-23 and treatment options for x-linked hypophosphatemia.

ASN gratefully acknowledges Amgen for support of the Jack W. Coburn, MD, Endowed Lectureship.

Learning Objective(s)

  • Describe the physiological role of FGF-23
  • Describe information on novel regulatory concepts for FGF-23
  • Discuss the treatment of x-linked hypophosphatemia

Learning Pathway(s)

  • Bone and Mineral Metabolism
  • Chronic Kidney Disease

Moderators

  • Tamara Isakova, MD
  • Carsten A. Wagner, MD

Presentations

  • Physiology and Pathophysiology of FGF23
    02:00 PM - 02:30 PM
    Orson W. Moe, MD
  • Genetic Variants Associated with Circulating FGF23
    02:30 PM - 03:00 PM
    Bryan R. Kestenbaum, MD, MS 
  • Historical Perspective in the Understanding of CKD-MBD: From Calcium to FGF-23 - The Jack W. Coburn, MD, Endowed Lectureship
    03:00 PM - 03:30 PM
    Sharon M. Moe, MD, FASN 
  • A Randomized Phase 3 Trial Evaluating the Efficacy of Burosumab in X-Linked Hypophosphatemia
    03:30 PM - 04:00 PM
    Thomas Carpenter, MD